2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum contribution to ProQR.
On behalf of all ProQRians, happy Rare Disease Day 2022. Both within ProQR and outside, we join the community in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, and supporters.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
… Pharmacokinetic and Pharmacodynamic Modelling Expert ProQR Therapeutics is a biotechnology company listed on … with common and rare diseases. A team of 170+ enthusiastic ProQRians from all walks of life and more than 30 different … team environment to progress the translational science in ProQR’s programs. The activities include: Prepare mechanistic …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
